Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists find potential toxoplasmosis drug target
Toxoplasmosis can be transmitted through soil, undercooked meat or from contact with cat faeces.
Study reveals enzyme that is crucial for the parasite’s survival

Researchers at the University of Glasgow have found a potential weakness in the Toxoplasma parasite that may eventually lead to a new drug target.

Writing in Plos Pathogens, scientists describe how they have found a key enzyme in the toxoplasmosis-causing parasite (thioredoxin) which is essential for its survival. The team are now working with industry partners to create new drugs that would target this enzyme and kill the parasite.

“More and more studies highlight the parasite’s sensitivity to redox imbalance – a key function of the enzyme we have studied,” said Dr Sheiner, from the University’s Wellcome Centre for Molecular Parasitology.

“Targeting the thioredoxin enzyme may make them vulnerable at stages of their life that are important for infection and dissemination. Finding enzymes in the parasite that we can target, and that don’t influence the human host, unravels this potentially deadly parasite’s Achilles’ heel.”

Toxoplasmosis is a common infection that is caused by the Toxoplasma parasite. It can be transmitted through soil, undercooked meat or from contact with cat faeces.

While most people who become infected with toxoplasmosis are not aware of it, the disease can be dangerous to unborn children and people with compromised immune systems.

Because the toxoplasmosis parasite is also used to learn about the biology of malaria-causing parasites, the team hope that their work will also lead to new drug targets for malaria.

Dr Sheiner said: “Our original interest in this research was not in drug discovery, rather we are excited to learn about how parasites work and how evolution provided them with special tools to serve their parasitic lifestyle. But, as in this case, we are obviously very happy if we stumble across promising targets for new drugs.”

Michael Chew, from Wellcome’s Infection and Immunobiology team, added: “Around a third of the UK population are thought to carry the Toxoplasma parasite. Normally a dormant parasite, it can lead to serious neurological harm when “awakened” in people with compromised immunity, like HIV patients, or those with an immature immune system, like infants and unborn children.

“This research is a great example of how basic, discovery science can lead to new drug targets for dangerous diseases.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.